- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Flibanserin Enhances Overall Sexual Function in Women with HSDD, Showing Early and Sustained Benefits: Study
![Flibanserin Enhances Overall Sexual Function in Women with HSDD, Showing Early and Sustained Benefits: Study Flibanserin Enhances Overall Sexual Function in Women with HSDD, Showing Early and Sustained Benefits: Study](https://medicaldialogues.in/h-upload/2024/09/09/750x450_251728-hypoactive-sexual-desire-disorder.webp)
USA: A recent study has shed light on the effectiveness of flibanserin in addressing Hypoactive Sexual Desire Disorder (HSDD) in women, revealing promising improvements across multiple dimensions of sexual function. Flibanserin, a drug originally approved for the treatment of HSDD, is known to target sexual desire specifically. However, new analyses published in Sexual Medicine suggest its benefits extend beyond mere desire, encompassing various aspects of sexual function.
Previous studies have shown that flibanserin treatment enhances sexual desire and satisfying sexual experiences while also reducing distress in some women with acquired, generalized hypoactive sexual desire disorder. However, the effects on other aspects of sexual function and the detailed timeline of response have yet to be fully explored. To fill this knowledge gap, Noel N. Kim, Institute for Sexual Medicine, San Diego, CA, USA, and colleagues aimed to assess changes in sexual function, as measured by the subdomains of the Female Sexual Function Index (FSFI), in women with HSDD undergoing treatment with flibanserin.
For the study, FSFI data from three pivotal trials involving premenopausal women treated with flibanserin (n=1,165) or placebo (n=1,203), as well as data from a complete trial involving postmenopausal women (flibanserin n=432; placebo n=463), were analyzed post-hoc.
The analysis focused on changes in FSFI subdomains, with least squares mean change from baseline calculated for each assessment visit at weeks 4, 8, 16, and 24. Treatment groups were compared using analysis of covariance, and standardized effect sizes (Cohen's d) were determined for each subdomain to evaluate the impact of treatment.
The study led to the following findings:
- Compared to placebo, both premenopausal and postmenopausal patients in the flibanserin group reported significantly greater increases over baseline in the FSFI subdomain scores of desire, arousal, lubrication, orgasm, and satisfaction.
- In premenopausal patients, significant improvements were observed at the first assessment of response (week 4) and were maintained through week 24.
- In postmenopausal patients, significant improvements were observed at week 4 for desire and arousal, while significant improvements in lubrication, orgasm, and satisfaction were observed at week 8.
- At week 24, excluding the pain subdomain, standardized effect sizes ranged from 0.18 to 0.28 in the premenopausal cohort and 0.12 to 0.29 in the postmenopausal cohort.
- In both pre- and postmenopausal patients, improvements in pain were smaller and largely undifferentiated between treatment groups.
The researchers conducted sexual function assessments in a substantial cohort of 2,368 premenopausal women and 895 postmenopausal women, a notable strength of the study. However, they acknowledged that the Female Sexual Function Index (FSFI) evaluates changes over one month, limiting the ability to assess time points earlier than four weeks.
According to the authors, although variations in time to response should be considered, flibanserin generally shows a beneficial impact on overall sexual function within the first month of treatment. The data also indicate that this positive response is maintained throughout treatment.
"These analyses indicate that evaluating the benefits of flibanserin for hypoactive sexual desire disorder (HSDD) should encompass improvements across all domains of sexual function, rather than focusing solely on sexual desire," the researchers concluded.
Reference:
Simon, J. A., Clayton, A. H., Goldstein, I., Kingsberg, S. A., Shapiro, M., Patel, S., & Kim, N. N. (2022). Effects of Flibanserin on Subdomain Scores of the Female Sexual Function Index in Women With Hypoactive Sexual Desire Disorder. Sexual Medicine, 10(6), 100570. https://doi.org/10.1016/j.esxm.2022.100570
MSc. Biotechnology
Medha Baranwal joined Medical Dialogues as an Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She has a working experience of 5 years in the field of medical research writing, scientific writing, content writing, and content management. She can be contacted at  editorial@medicaldialogues.in. Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: editorial@medicaldialogues.in. Contact no. 011-43720751